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ABSTRACT	
Role	of	Spastin	in	regulating	glioblastoma	cell	survival		Dimpi	Mukhopadhyay	Mauricio	J.	Reginato,	Ph.D		Glioblastomas	 are	 the	most	 aggressive	 form	 of	 brain	 tumors	 and	 the	most	 abundant	malignant	 glioma	 among	 adults.	 These	 are	 notoriously	 aggressive	 cancers	 with	 the	median	survival	of	14.6	months	after	diagnosis.	Thus,	different	strategies	and	targeted	therapies	are	needed	in	order	to	 improve	prognosis	and	survival.	Microtubules	are	an	essential	machinery	 to	ensure	proper	cell	division	and	proliferation.	Uncontrolled	cell	division	is	the	primary	hallmark	of	cancer	cells	hence	microtubule-targeting	drugs	are	widely	 used	 in	 cancer	 therapeutics.	 However,	 resistance	 to	 those	 drugs	 has	 been	 a	major	hurdle	that	has	compromised	their	success.	In	that	regard,	different	microtubule	associated	 proteins	 that	 affect	 its	 dynamic	 nature	 are	 widely	 explored	 as	 targets	 for	cancer	 therapeutics.	Spastin	 is	a	microtubule	severing	ATPase	 that	directly	modulates	the	dynamics	of	microtubules	and	Spastin	levels	have	been	shown	to	be	elevated	in	the	glioblastomas.	Our	 lab	has	 recently	 shown	 that	 targeting	Spastin	 in	glioblastoma	cells	causes	restriction	 in	 tumor	growth	 in	an	orthotopic	xenograft	mouse	model.	Here,	we	show	that	inhibiting	Spastin	using	two	different	shRNAs	in	glioblastoma	cells:	U87	and	T98Gs,	 induces	apoptosis	with	a	 reduction	 in	 the	apoptotic	marker	cleaved-PARP	and	downregulates	 the	 anti-apoptotic	 protein	 Bcl-2.	 Consistently,	 we	 noticed	 that	 Spastin	depletion	using	 shRNAs	 reduced	 cell	 attachment.	 Indeed,	we	 show	 that	 the	 adhesion-dependent	 signaling	 pathways,	 Erk	 and	 p38	 are	 reduced	 upon	 Spastin	 depletion	 in	glioblastoma	 cells.	 Thus,	 Spastin	 maintains	 glioblastoma	 cell	 survival	 and	tumorigenicity	by	maintaining	 the	pro-survival	 signaling	pathways	 in	 the	 cancer	 cells	and	may	represent	a	novel	therapeutic	target	in	glioblastoma.			
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INTRODUCTION	
			One	of	the	most	aggressive	forms	of	cancers	is	a	malignant	brain	tumor	owing	to	their	poor	 prognosis	 and	 its	 direct	 influence	 on	 cognitive	 function	 and	 the	 quality	 of	 life.	Among	malignant	gliomas,	glioblastomas	are	the	primary	most	abundant	form	in	adults	with	over	80%	patients	 and	5.26	per	100,000	patients	 (2).	 Since	 it	 is	more	prevalent	among	adults,	it	seems	to	more	often	affect	individuals	over	60	years	of	age	than	others	(Ref).	 	 They	 arise	 in	 the	 astrocytes	 in	 the	 brain.	 Like	 every	 other	 cancer,	 the	 WHO	broadly	 divides	 gliomas	 into	 several	 histological	 grades	 based	 upon	 the	 degree	 of:	anaplasia,	 undifferentiated	 state	 and	 finally	 aggressiveness	 with	 the	 higher	 grade	having	 the	highest	degree	of	 the	above	 three	 (3).	 	They	not	only	 contribute	 to	a	poor	prognosis	 but	 in	 terms	 of	 quality	 of	 life	 they	 have	 adverse	 effects.	 Grade	 II	 tumors,	which	include	the	diffused	astrocytomas	and	the	oligodendrogliomas,	consist	of	higher	degree	of	differentiated	neoplasms	and	thereby	pose	a	greater	threat	of	progressing	to	a	higher	 grade	 of	 tumor.	 Glioblastomas	 however	 are	 highly	 invasive	 approaching	 the	surrounding	brain	parenchyma	tissue.	It	accounts	for	82%	of	malignant	tumors.	In	spite	of	its	invasive	properties,	glioblastomas	are	not	very	metastatic	and	are	only	confined	to	the	 central	 nervous	 system.	 The	 primary	 line	 of	 treatment	 of	 glioblastoma	 includes	surgery	 to	 relieve	 brain	 pressure	 followed	 by	 radiation.	 Recently,	 radiation	 has	 been	accompanied	by	an	adjuvant	Temozolomide	treatment.	And	even	with	that	the	median	survival	 is	14.6	months	 from	 the	point	of	diagnosis.	Furthermore,	genomic	studies	by	several	groups	that	identified	mutations	and	gene	copy	number	changes	enhanced	the	understanding	 of	 the	 different	 subtypes	 of	 Glioblastoma	 (1).	 Thus	 new	 therapeutic	strategies	need	to	be	developed	for	improving	the	median	survival.		
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In	the	field	of	anti-cancer	drugs,	microtubule	targeting	drugs	have	been	popular	as	they	help	 to	 arrest	 cell	 division,	 which	 is	 the	 primary	 hallmark	 of	 many	 cancer	 cells,	uncontrolled	cell	division.	Microtubules	are	filamentous	structures	that	are	functionally	indispensible	 for	 eukaryotic	 cells	 serving	 several	 purposes	 including	 cell	 division,	intracellular	transport	and	intracellular	structural	organization.	The	crucial	part	is	that	the	 assembly	 and	disassembly	 of	microtubules	 regulate	 their	 functionality.	Alpha	 and	beta	tubulins	form	heterodimers	that	are	then	arranged	into	filaments	to	make	up	the	microtubules.	Alpha	and	beta	tubulins	are	50	KDa	each	and	bear	almost	50%	similarity	to	each	other	(4).	In	order	to	form	the	microtubules	tubulins	need	to	polymerize	which	happens	in	a	unique	way	of	nucleation	elongation	and	this	involves	formation	of	a	short	microtubule	 nucleus	 to	 which	 the	 tubulin	 dimers	 are	 added	 noncovalently	 (5).	 The	arrangements	 for	 the	polymerization	 involve	the	heterodimers	added	 in	a	head	to	tail	fashion	with	the	alpha-subunit	of	one	tubulin	binding	to	the	adjacent	beta	subunit	of	the	adjacent	dimer.	Repeated	cycles	of	these	start	giving	rise	to	the	protofilaments	with	a	25	nm	 diameter	 hollow	 core	 (5).	 The	 afore-mentioned	 alpha-beta	 tubulin	 attachment	makes	the	protofilament	and	gives	a	polarity	to	the	microtubule	network	with	a	minus	and	plus	end,	which	is	basically	alpha-tubulin	and	beta-tubulin	ended	respectively	(5).	A	group	of	proteins	called	the	microtubule	associated	proteins	make	up	the	microtubule	organizing	center,	at	which	site	the	microtubules	are	anchored	by	the	minus	ends	with	the	plus	ends	protruding	out.																One	of	the	distinct	features	of	microtubules	is	their	dynamic	nature	caused	as	a	result	 of	 the	 disassembly	 and	 assembly	 of	 tubulin	 sub-units	 and	 both	 assembly	 and	disassembly	is	favored	at	the	plus	end	over	the	minus	end	(4)	The	alpha	and	beta	sub-units	 are	 also	 associated	 with	 Guanosine	 nucleotide	 triphosphate	 (GTP),	 which	 is	hydrolysable	to	GDP;	however,	the	GTP	bound	to	alpha-sub	unit	is	more	stable	than	that	
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on	beta	and	it	is	the	state	of	the	nucleotide	bound	on	beta	subunit	that	determines	the	stability	of	the	microtubule.	The	ability	of	assembly	and	disassembly	of	the	microtubule	components	 confers	 it	 with	 a	 dynamic	 nature.	 This	 switch	 between	 association	 and	dissociation	is	the	result	of	GTP	binding	and	hydrolysis	at	the	ends	of	the	microtubules.	A	 microtubule	 is	 considered	 stable	 when	 it	 has	 a	 GTP	 cap;	 however,	 when	 the	hydrolysis	of	GTP	catches	up	to	the	end	and	it	is	GDP	bound,	it	is	rapidly	disassociated,	which	is	often	referred	to	as	catastrophe	(As	shown	in	Figure	1;	Ref	4,	6).	Thus,	the	GTP	binding	 and	 hydrolysis	 contributes	 directly	 to	 the	 dynamic	 nature	 of	 microtubules	leading	to	two	features:	treadmilling	and	dynamic	instability	(4).	Instability	refers	to	the	phases	of	addition,	dissociation	and	rescue	of	the	microtubule	filaments	(4).	The	step	of	adding	the	tubulin	sub-units	on	the	plus	end	with	the	concomitant	dissociation	from	the	minus	 end	 refers	 to	 Treadmilling	 (4).	 Microtubules	 are	 present	 in	 the	 cells	 during	interphase	 and	 mitosis.	 Owing	 to	 their	 function	 in	 cell	 division,	 microtubules	 are	particularly	 dynamic	 at	 mitosis	 and	 are	 sensitive	 to	 inhibitors	 at	 this	 point.	 Hence	microtubule	 targeting	 molecules	 have	 been	 exploited	 to	 selectively	 kill	 cancer	 cells.	These	anti-mitotic	agents	are	mostly	obtained	from	natural	sources.	Depending	on	their	mode	 of	 action,	 they	 can	 be	 destabilizing	 or	 stabilizing	 agents,	 which	 refers	 to	 their	effects	on	microtubule	filaments	at	high	concentrations.	Thus,	at	high	concentrations	as	the	 name	 suggests,	 destabilizing	 agents	 prevent	 the	 polymerization	 of	 microtubules.	They	usually	act	by	binding	to	either	of	the	domains	of	the	tubulins.		
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Figure1:	Microtubule	dynamics	
	Microtubule	 filaments	 are	 composed	 of	 the	 alpha	 and	 beta	 tubulin	 sub-units	 and	 it	
polymerizes	when	the	end	is	GTP	bound.	However	as	the	GTP	gets	hydrolyzed	and	catches	
up	to	the	end	of	the	microtubule,	it	initiates	the	depolymerization	leading	to	Catastrophe.	
This	 dissociation	 however	 can	 be	 reversed	 by	 addition	 of	 GTP	 bound	 alpha	 and	 beta-
tubulins	at	the	leading	edge	that	would	initiate	the	Polymerization	again	and	this	part	is	
referred	to	as	Rescue.			Microtubules	 are	 indispensable	 for	 cell	 division	 and	 therefore	 interrupting	 their	dynamics	causes	cell	cycle	arrest	eventually	leading	to	cell	death.	There	are	two	classes	
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of	such	inhibitors:	Microtubule	stabilizing	and	destailizing	agents	based	on	their	effects	on	microtubule	 polymerization	 at	 low	 concentrations.	 Vinca	 alkaloids	 are	 one	 of	 the	major	inhibitors	that	belong	to	the	destabilizing	agents;	they	have	a	binding	site	on	the	beta-tubulin	 where	 the	 GTP	 binds.	 They	 have	 a	 higher	 affinity	 towards	 the	 ends	 of	microtubules;	however	they	also	attach	to	 the	sides	of	 it	but	with	much	 lower	affinity	(7).	 Thus,	 they	 allow	 restricting	 the	 mitotic	 progression	 by	 inhibiting	 the	 dynamic	instability	 and	 finally	 causing	 cell	 death.	 Vinca	 alkaloids	 are	 extensively	 used	 in	treatment--either	 exclusively	 or	 in	 combination	 with	 other	 cytotoxic	 reagents	 in	treatment	 regimens	 of	 patients	with	 solid	 tumors	 and	 hematologic	malignancies.	 The	other	 group	 of	 stabilizers	 include	 Taxanes,	 which	 are	 also	 natural	 products	 isolated	from	Taxus	baccata	(8).	These	bind	to	the	beta	sub-unit	as	well	but	on	the	interior	side	enhancing	 polymerization	 and	 thereby	 arresting	 the	 instability	 and	 the	 cell-cycle	 (9,	10).	Some	of	the	popular	taxane	drugs	include	Paclitaxel	and	Docetaxel.	Paclitaxel	and	Docetaxel	 are	 approved	 for	 approved	 for	 the	 treatment	 of	 breast	 and	 non-small	 lung	cancer	 (11,	12).	 Furthermore,	Paclitaxel	has	 shown	some	promising	outcomes	 for	 the	treatment	of	advanced	carcinoma	of	the	ovary	whereas	Docetaxel	has	shown	promise	in	androgen-independent	prostate	cancer	(11,	12).		In	spite	of	the	success	of	the	microtubule	targeting	drugs	and	their	extensive	use	in	the	treatment	of	cancer,	resistance	against	them	is	one	of	the	major	hurdles	that	prevents	the	success	of	these	drugs.	The	P-glycoprotein	(P-gp)	efflux	pump	is	one	of	the	primary	causes	of	resistance	to	the	MTIs	as	well	as	other	chemotherapeutic	drugs.	It	is	the	Multi-drug	resistance	gene	(MDR1)	gene	product	(13).	Another	major	resistance	mechanism	is	 alteration	of	 the	 tubulin	binding	 sites,	 precisely	 the	 sites	where	 the	 vinca	 alkaloids	and	taxanes	bind.	Data	from	the	ovarian	cancer	patients	showing	resistant	to	Paclitaxel	has	revealed	mutation	in	the	βI-isotype	of	tubulin	encoded	by	the	M40	gene	(14).	βIII-
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isotype	of	tubulins	are	often	seen	to	make	up	the	microtubules	that	are	slightly	different	in	 that	 it	 requires	 a	 greater	 critical	mass	 for	 assembly	 and	also	polymerizes	 at	 a	 rate	slower	 than	 others	 (15).	 Certain	 in-vitro	 experiments	 have	 revealed	 that	 over-expression	of	 this	β-III	 isotype	can	cause	resistance	to	 taxanes	as	well	as	vinorelbrine	(16,	 17).	 Clinical	 data	 also	 shows	 that	 expression	 of	 this	 β-III	 isotype	 relates	 to	resistance	 to	 taxanes	by	 the	 tumors	 (18).	 In	 studies	 involving	patients	with	advanced	breast	cancer	receiving	Paclitaxel	as	a	primary	chemotherapy,	 the	tumor	 in	2%	of	 the	patients	 seemed	 to	 progress	 and	 those	 happen	 to	 have	 an	 expression	 of	 β-III	 tubulin	(19).	Similar	resistive	reaction	even	to	Docetaxel-based	chemotherapy	was	observed	in	advanced	 breast	 cancer	 patients	 with	 elevated	 expression	 of	 β-III	 and	 β-I	 tubulin	isotype	 (20).	 In	NSLC	and	ovarian	cancer	patients,	 the	poor	response	 to	 taxane-based	therapy	was	once	again	correlated	to	the	expression	of	the	two	isotypes	of	tubulin	(21,	22).	 Besides	 these	 two	 reported	 isotypes,	 there	 are	 several	 other	 proteins	 associated	with	 the	 microtubules	 that	 are	 also	 responsible	 to	 therapy	 responsiveness.	Overexpression	of	 the	microtubule	 regulatory	protein,	 Stathmin,	which	 is	 responsible	for	 destabilization,	 is	 correlated	 to	 resistance	 to	 paclitaxel	 and	 vinblastine	 in	 breast	cancer	patients	(23).	Furthermore,	expression	of	an	isoform	of	the	cytoskeletal	protein	gamma-actin	is	related	with	vinblastine-resistance	in	leukemia	and	NIH	3T3	cells	(24).		Thus,	 current	 clinical	and	experimental	data	 suggests	 that	overexpression	of	different	isotypes	and	point	mutation	of	drug	binding	sites	are	causing	resistance	to	the	MTIs	and	that	is	major	hurdle	in	the	prognosis	and	better	survival	of	patients.	There	are	several	other	 proteins	 that	 orchestrate	 the	dynamics	 of	 the	microtubule	 network	besides	 the	tubulin	sub-units,	e.g.	 the	motor	protein	Kinesin-5,	which	is	recently	being	targeted	in	cancer		(25).		
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			There	 is	 another	 group	of	 proteins	 that	 are	 solely	 responsible	 for	 severing	 the	 long	microtubules	into	shorter	ones,	which	have	not	received	much	attention	with	respect	to	cancer	therapeutics.	Katanin	and	Spastin	are	the	two	enzymes	that	belong	to	that	class.	These	shorter	microtubules	have	important	roles	as	they	can	move	through	axonal	and	glial	cytoplasm.	(26,27).	The	SPG4	gene	encodes	Spastin,	which	belongs	 to	 the	AAA	 family	of	proteins	hence	 it	requires	ATP	hydrolysis	for	microtubule	severing.	The	ATPase	domain	of	the	protein	is	on	the	C-terminus,	which	is	220	amino-acid	long	(28);	however	the	microtubule	binding	domain	 (amino-acid:	 270-328)	 is	 present	 on	 the	 N-terminus.	 Spastin	 has	 roles	 in	trafficking	 and	 organelle	 biogenesis	 and	 the	 N-terminus	 contains	 the	 endosomal	trafficking	 domain.	 (29).	 Extensive	 biochemical	 experiments	 have	 revealed	 that	 both	the	 microtubule-binding	 domain	 and	 the	 ATPase	 domain	 are	 indispensable	 for	 its	microtubule	 severing	activity	 (29).	Unlike	katanin,	which	 is	ubiquitously	expressed	 in	every	 tissue,	 Spastin	 expression	 is	 restricted	 to	 the	 central	 nervous	 system	 with	constitutive	 expression	 in	 the	 neurons	 and	 induced	 expression	 in	 reactive	 astrocytes	(30,	 31).	 There	 are	 several	 isoforms	 of	 Spastin	 which	 are	 synthesized	 as	 a	 result	 of	different	 translation	 start	 sites	 (start	 codons)	 and	 also	 depending	 on	 certain	 exons	being	included	or	excluded	during	splicing	(32).	As	a	result	of	these	alternate	start	sites,	there	 is	a	 long	 isoform	that	was	 found	 in	rat	 tissue	referred	 to	as	M1	and	 the	shorter	isoform	as	M87	(33).	Besides	its	role	in	microtubule	severing,	Spastin	became	popular	due	 to	 its	 association	with	 the	most	 abundant	 form	 of	 Hereditary	 Spastic	 Paraplegia	(HSP).	Mutation	in	the	SPG4	gene	is	associated	with	the	most	abundant	(approximately	40%)	autosomal	dominant	form	of	HSP.	Several	genes	have	been	held	responsible	to	the	Autosomal	 dominant	 form	 of	 HSP	 including	 SPG4	 on	 chromosome	 14q2p.	 (34).	 The	characteristics	 of	 both	 familial	 and	 hereditary	 HSP,	 include	 typical	 characteristic	
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spasticity	that	is	progressive	and	bilateral	in	lower	limbs.	(35).	Another	marked	feature	of	HSP	is	axonal	degeneration	(35).	This	sheds	some	light	 into	Spastin’s	role	in	axonal	branching.	Through	seven	pedigrees,	DNA	analysis	 revealed	 that	mutations	 in	Spastin	cause	AD-HSP,	including	missense,	nonsense	and	splice	site	mutation	(36).	The	central	nervous	 system	 functionality	 depends	 on	 the	 proper	 branching	 of	 axons	 that	 again	demands	 drastic	 cytoskeletal	 remodeling	 in	 the	 parental	 axon.	 This	 remodeling	 is	carried	out	by	making	shorter	mobile	microtubules	from	the	long	ones	and	thereby	by	the	 severing	 proteins	 namely	 Katanin	 and	 Spastin.	 The	 presence	 of	 two	 different	enzymes	for	the	same	function	seems	redundant	but	this	system	is	essential	for	proper	axonal	 branching	 and	 nervous	 system	 development.	 Thus	 there	 is	 a	 speculation	whether	 they	 have	 independent	 roles	 in	 ensuring	 that	 or	 together	 they	maintain	 the	fidelity	of	the	system.	In	fact	it	was	found	that	they	might	have	independent	roles	in	the	nervous	system	one	having	more	effect	than	the	other.	Experimental	evidence	suggests	that	Spastin	depletion	in	rat	hippocampal	neurons	compromises	the	axon	branches	and	minor	processes	greater	than	Katanin.											While	recognized	as	an	essential	protein	in	the	proper	development	of	the	nervous	system	by	 controlling	axonal	branching,	 Spastin	has	not	 received	 significant	 attention	regarding	its	status	in	brain	tumors.	One	of	the	first	reports	of	Spastin	in	glioblastoma	revealed	 that	 it	 was	 upregulated	 at	 the	 transcript	 level	 in	 the	 glioblastoma	 cell	 lines	U87,	T98G,	U138	as	well	as	 in	a	neuroblastoma	cell	 line	SK-N-SH	(37).	Following	this,	our	 lab	 has	 demonstrated	 that	 Spastin	 is	 not	 only	 upregulated	 but	 required	 by	glioblastoma	 cells,	 such	 that	 its	 inhibition	 reduces	 tumorigenicity	 in-vitro	 (soft	 agar	assay)	 as	well	 as	 restricts	 tumor	 growth	 in	 a	 xenograft	mouse	model.	 Hence	 there	 is	evidence	that	glioblastoma	cells	require	Spastin	 for	their	growth	and	survival	but	 it	 is	not	 clear	 why	 or	 how	 it	 helps	 it.	 Here	 we	 have	 looked	 mechanistically	 at	 what	 is	
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occurring	 with	 Spastin	 inhibition	 in	 glioblastoma	 cells	 as	 they	 fail	 to	 maintain	 their	tumorigenicity.	 We	 show	 that	 depleting	 Spastin	 in	 Glioblastoma	 cells	 U87	 and	 T98G	causes	 cell	 death	 by	 apoptosis	 indicated	 by	 an	 upregulation	 of	 apoptotic	marker	 like	cleaved-PARP.	We	also	confirmed	a	consistent	 increase	 in	 the	apoptotic	population	 in	the	Spastin	knockdown	cells	compared	to	the	control.	Furthermore,	glioblastoma	cells	with	 Spastin	 knockdown	 have	 reduced	 pro-survival	 signaling	 proteins,	 p-ERK	 and	 p-p38	 than	 the	 control	 cell,	which	partly	 explains	 the	distinct	phenotype	of	 knockdown	cells	losing	attachment.				 	
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MATERIALS	AND	METHODS		
Cell	lines	and	culture	conditions:	Glioblastoma	 cell	 lines	 U87MG	 and	 T98G	was	 purchased	 from	ATCC	 (American	 Type	culture	collection,	Manassas,	VA,	USA)	and	grown	in	Dulbecco	modified	eagle	medium	(DMEM)	 supplemented	 with	 10%	 fetal	 bovine	 serum	 (FBS),	 5	 mL	 Penicillin	 and	Streptomycin	 antibiotics.	 Cell	 cultures	 were	 incubated	 at	 37°C	 in	 a	 humidified	atmosphere	with	5%	CO2.	Cells	were	harvested	by	0.25%	trypsin-EDTA	and	centrifuged	for	3	minutes	at	1100	rpm.	Supernatant	was	aspirated	and	5	mL	of	DMEM	media	was	to	re-suspend	the	pellet.		
Lentiviral	transduction:	VSVG-pseudotyped	lentivirus	was	generated	by	the	cotransfection	of	293-T	packaging	cells	with	10	μg	of	DNA	and	5	μg	of	packaging	vectors	as	described	previously	(Rubinson	et	al.,	2003).	Cells	were	infected	and	selected	as	described	previously	(Reginato	et	al.,	2003).	Lentiviruses	wwere	used	to	transduce	U87	and	T98G	cells		
shRNA	transfections	shRNA	1:	5’-CAACCTTGCTAACCTTATA-3’;	and	shRNA	3:	5’-GGA	AGUCCATTGACCCAAA-3’.				
Antibodies:	A	rabbit	polyclonal	antibody	(Sp/AAA)	immunoblotting	experiments	in	1:1000	dilution	used	 for	 Spastin.	 The	 Sp/AAA	 antibody	was	 raised	 against	 the	 recombinant	 fragment	coding	mouse	spastin	polypeptide	(amino	acids	[a.a.]	337Y446).		Anti-rabbit	polyclonal	cleaved-PARP	antibody	(Cell	signaling:	9541S)	was	used	that	detects	the	cleaved-PARP	fragment	 at	 89	KDa.	 Anti-mouse	monoclonal	 Bcl-2	 antibody	was	 used	 (CST:	 2876)	 in	1:1000	dilution.		
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Cell	lysate	and	western	blot	ananlysis:	Cell	 lysates	from	1–5x106	cells	were	prepared	in	RIPA	lysis	buffer	(150	mM	NaCl,	1%	NP40,	0.5%	DOC,	50	mM	Tris-HCl	at	pH	8,	0.1%	SDS,	10%	glycerol,	5	mM	EDTA,	20	mM	NaF	 and	 1	 mM	 Na3VO4)	 supplemented	 with	 1	 mg/ml	 each	 of	 pepstatin,	 leupeptin,	aprotinin	 and	 200mg/ml	 phenyl-methyl-	 sulfonyl-fluoride.	 Lysates	 were	 cleared	 by	centrifugation	 at	 16000g	 for	 20min	 at	 41C	 and	 analyzed	 by	 SDS–PAGE	 and	autoradiography.	Proteins	were	analyzed	by	immunoblotting	using	primary	antibodies	indicated	above.		
Flow	cytometry:	7	days	post-infection	with	control	or	Spastin	shRNA	lentivirus,	cells	were	harvested	and	washed	with	PBS.	Pellets	were	resuspended	in	1X	Annexin	V	Buffer	as	per	Annexin	V:	FITC	Apoptosis	Detection	Kit	II	(BD	Biosciences)	manufacturers	protocol.	All	data	were	collected	and	analyzed	using	a	Guava	EasyCyte	Plus	system	and	CytoSoft	(version	5.3)	software	(Millipore).	Apoptosis	data	are	presented	as	the	percent	fluorescence	intensity	of	gated	cells	positive	for	Annexin	V	and	Propidium	Iodide.		
Statistics:	Statistical	analysis	was	performed	using	Excel	and	results	were	expressed	as	mean	SE.	Statistically	significant	differences	were	determined	by	Student’s	t	test.	P-values	<0.05	were	considered	statistically	significant.			 	
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RESULTS	
	
A.	Spastin	depletion	induces	apoptosis	in	glioblastoma:	Glioblastoma	is	known	to	be	one	of	the	most	aggressive	and	malignant	forms	of	gliomas	arising	 at	 the	 astrocytes.	 Katsetos	 et.	 al,	 showed	 that	 Spastin	 is	 elevated	 in	 the	glioblastoma	U87	and	T98G	at	the	mRNA	level.	 It	was	also	observed	that	reducing	the	levels	of	Spastin	using	shRNA	in	U87	and	T98G	compromised	the	tumorigenic	potential	of	the	cells	in-vitro	using	Soft	agar	assay	(Figure	5).	Depletion	of	Spastin	further	caused	reduced	 tumor	 growth	 in	 an	 in-vivo	 xenograft	 mice	 model	 (Figure	 5).	 Thus,	 data	strongly	suggested	Spastin	was	required	for	the	tumorigenicity.							Looking	 further	 into	how	Spastin	depletion	 affects	 the	 survival	 of	 the	 glioblastoma	cells,	 Spastin	was	depleted	with	 two	different	 shRNAs	 in	U87s.	Western	blot	 analysis	from	 the	 control	 and	 Spastin	 depleted	 cells	 showed	 an	 elevation	 in	 the	 apoptotic	markers,	 cleaved-PARP	 and	 pro-apoptotic	 proteins	 like:	 Bax	 and	 down-regulation	 of	anti-apoptotic	proteins	Bcl-2	 (Figure	2).	A	 similar	 effect	 in	 the	 levels	 of	 the	 apoptotic	proteins	was	also	observed	with	the	Spastin	depletion	in	the	T98G	glioblastoma	cells.		
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Figure	2:	Spastin	is	required	by	glioblastoma	cells	to	maintain	tumorigenicity	
A:	Colonies	formed	by	U87	control	and	U87	shspastin1	and	shspastin	3	cells	in	soft	agar	
and	quantification	of	the	same.	There	was	significant	reduction	in	colony	forming	ability	
in	soft	agar	in	Spastin	knockdown	cells.	
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B:	The	effect	of	Spastin	depletion	was	 investigated	 in	vivo	using	an	orthotopic	xenograft	
mouse	model	where	U87MG	cells	 expressing	 luciferase	 (targeted	 to	 knockdown	Spastin)	
were	stereotactically	implanted	into	brains	of	nude-/-	mice.	Tumor	growth	was	monitored	
by	 bioluminescence	 imaging.	 Bioluminescence	 signals	 in	 sh-control	 mouse	 (on	 the	 left	
panel)	and	sh-spastin	mouse	(on	the	right)	detected	from	days	7	to	19	post-injection.	By	
comparison,	 bioluminescence	 signals	 are	 significantly	 of	 lower	 intensity	 in	 sh-spastin	
mouse	through	day	19.		
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Figure	3:	Spastin	depletion	causes	apoptosis	
A:	Apoptotic	marker	cleaved-PARP	increase	in	U87	and	T98G	sh-spastin1	and	sh-spastin	3	
cells.	 Pro-apoptotic	 protein	 Bax	 increases	 and	 anti-apoptotic	 protein	 Bcl-2	 decreases	 in	
the	U87	and	T98G	knockdown	cells	compared	to	the	sh-control.	
B:	Quantification	of	cleaved-PARP	reveals	it	 is	significantly	higher	in	U87	sh-spastin	cells	
compared	to	the	sh-control	cells.		
	
B.	Spastin	inhibition	increases	the	apoptotic	population	in	glioblastoma	cells:	The	levels	of	the	apoptotic	markers	through	western	blot	analysis	on	Spastin	depletion	made	us	look	further	into	it.	To	confirm	the	effect	of	Spastin	depletion	on	apoptosis	the	early	 and	 late	 apoptotic	 population	was	 quantified	 using	 flow	 cytometry.	 In	 a	 similar	approach	 using	 two	 different	 shRNAs	 Spastin	was	 depleted	 in	 the	 Glioblastoma	 cells	then	using	flow	cytometry	of	Annexin	V	and	PI	staining	the	early	and	the	late	apoptotic	
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population	was	quantified.	As	expected	the	desired	population	was	much	higher	in	the	Spastin	knockdown	glioblastoma	compared	to	the	control.		
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Figure	4:	Inhibiting	Spastin	increases	the	apoptotic	population	
A:	 The	 early	 and	 late	 Apoptotic	 population	 (Annexin-V+/PI+	 and	 Annexin-V+)	 is	
significantly	higher	in	U87	shspastin	1	and	3	compared	to	the	shcontrol	cells.		
B:	 Similar	 trend	 of	 increase	 in	 the	 early	 and	 apoptotic	 population	 is	 seen	 in	 Spastin	
depleted	T98G	cells.			
C.	Effects	of	Spastin	depletion	in	survival	signaling	proteins:	Flow	 cytometry	 data	 showed	 greater	 apoptotic	 population	 in	 spastin	 depleted	 cells.	Furthermore,	 on	 inhibiting	 spastin	 cells	 seem	 to	 lose	 attachment	 (as	 shown	 in	Figure	
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5A)	 that	might	be	 affecting	 their	 integrin	 and	other	downstream	survival	 signaling	 in	turn.	 In	order	 to	 investigate	whether	 levels	of	signaling	proteins	varied	under	Spastin	inhibition	 in	 GBMs,	 western	 blot	 analysis	 was	 performed	 on	 control	 and	 Spastin	depleted	 cells	 to	 determine	 levels	 of	 signaling	 proteins,	 p-p38	 and	 p-Erk.	 Indeed	 the	levels	 of	 p-p38	 and	 p-Erk	 decreased	 while	 the	 total	 Erk	 and	 total	 p-38	 remained	constant	in	the	Spastin	depleted	glioblastoma	cells	compared	to	the	control.		 	 	
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Figure	5:	Spastin	depletion	decreases	levels	of	signaling	proteins	
A:	Spastin	knockdown	U87	lose	attachment	to	the	basement	compared	to	the	control	cells.	
B:	Inhibition	of	Spastin	in	U87	and	T98G	with	shspastin	1	and	3	decreases	levels	of	p-Erk	
and	p-p38.	
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DISCUSSION:	Glioblastoma	multiforme	 arises	 at	 the	 astrocytes	 and	 due	 its	 heterogeneous	 nature	 it	was	 termed	 Glioblastoma	 multiforme.	 They	 are	 the	 most	 malignant	 form	 of	 brain	tumors	 having	 a	 median	 survival	 of	 only	 14.6	 months	 with	 the	 currently	 available	therapy.	These	aggressive	tumors	have	a	poor	prognosis	along	with	a	very	low	quality	of	 life	 owing	 to	 the	 adverse	 effects	 on	 cognitive	 function.	 Temozolomide	 is	 a	 DNA	alkylating	agent	utilizing	the	principle	of	inflicting	DNA	damage	enough	that	drives	the	cancer	 cells	 to	 cell	 death.	 Clinical	 data	 from	 patients	 does	 suggest	 that	 response	 to	Temozolomide	 is	better	 across	 a	patient	 cohort	 that	 exhibits	hypermethylation	at	 the	MGMT	promoter.	Considering	the	present	therapy	scenario,	 there	are	several	drugs	 in	clinical	 trial	 for	 malignant	 gliomas	 patients.	 One	 of	 the	 forerunners	 is	 the	 use	 of	Velaparib	 in	 combination	 with	 Temozolomide	 against	 a	 cohort	 of	 patients	 that	 have	recently	 diagnosed	 with	 GBM	 and	 harbor	 MGMT	 hypermethylation	 in	 the	 tumor.	Temozolomide	 causes	 DNA	 damage	 and	 then	 combining	 it	 with	 the	 PARP	 inhibitor,	Velaparib	would	make	it	more	effective	 in	breaking	down	the	cancer	cells	and	driving	them	 to	 apoptosis.	 Besides	 these	 most	 of	 the	 other	 drugs	 in	 clinical	 trial	 are	immunotherapy	drugs	designed	 to	 target	 the	 tumor	 cells.	One	of	 the	most	prominent	ones	 in	 this	respect	 is	 the	use	of	 ICT-107,	which	 involves	using	dendritic	cells	primed	with	 synthetic	 peptides	 from	 the	 Tumor	 associated	 antigens	 (TAA).	 These	 dendritic	cells	are	expected	to	launch	a	cytotoxic	T	cell	response	directed	specifically	against	the	tumor	 cells	 and	 thereby	 induce	 cell	 death.	 One	 of	 the	 biggest	 challenges	 in	immunotherapy	 success	 has	 been	 the	 heterogeneity	 of	 tumors	 and	 its	 inability	 to	effectively	target	the	entire	population.	Secondly,	with	brain	tumors	the	biggest	hurdle	has	been	to	get	drugs	 to	cross	 the	blood	brain	barrier	 to	attack	 the	 tumor	cells	 in	 the	first	place.	Hence	the	search	for	better	drugs	and	targeting	molecules	is	always	open	for	
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these	malignant	tumors.	Microtubule	inhibitors	have	been	used	from	the	early	days	of	cancer	 therapeutics	owing	 to	 the	 role	of	microtubules	 in	mitosis.	Thus	use	of	 taxanes	and	vinca	alkaloids	against	in	solid	tumors	and	hematologic	malignancies	are	common	in	 cancer	 (3).	 Recently	 Paclitaxel	 has	 been	 extensively	 used	 against	 advanced	 breast	cancer	Docetaxel	 in	 prostate	 cancer	 and	 this	 treatment	 has	 received	 some	 setup	 in	 a	certain	group	of	patients.	Besides	this,	there	has	been	a	increasing	reports	of	resistance	to	the	MTIs	in	different	cancer	(11,	12).	There	are	several	reasons	for	the	resistance,	the	most	popular	ones	being	the	mutation	at	 the	drug	binding	sites	and	the	expression	of	alternate	isotypes	of	tubulins	like	βII,	βI-tubulin.	As	a	matter	of	fact	the	2%	of	advanced	breast	cancer	patients	that	do	not	respond	to	Paclitaxel	express	βIII-tubulin	(11).	In	this	situation	other	microtubule-associated	proteins	are	being	explored	as	potential	targets	that	 includes	 the	 motor	 protein	 Kinesin	 and	 severing	 enzymes,	 Katanin	 and	 Spastin.	Most	of	 the	 studies	on	Spastin	have	been	 restricted	 to	 its	 association	with	Autosomal	dominant	 form	 of	 Hereditary	 Spastic	 Paraplegia	 (HSP)	 and	 directed	 towards	determining	 the	mutations,	which	 are	 responsible	 for	 the	 condition.	 It	 has	 now	 been	established	 that	 mutations	 in	 the	 ATP	 binding	 as	 well	 as	 the	 microtubule-binding	domain	can	cause	axonal	degeneration,	one	of	the	features	of	HSP	(36).	However	being	a	protein	that	is	exclusively	expressed	in	the	nervous	system	it	has	been	overlooked	in	the	 context	 of	 brain	 tumors.	 Only	 recently,	 one	 of	 the	 first	 reports	 of	 Spastin	 in	association	with	malignant	gliomas	showed	through	Immunohistochemistry	that	there	was	higher	stain	of	Spastin	in	Glioblastoma	than	in	normal	brain.	Moreover	in	the	GBM	cell	lines	Spastin	was	upregulated	compared	to	the	normal	astrocytes	at	the	transcript	level	 (37).	 This	 information	 opened	 up	 new	 areas	 of	 research	 on	 Spastin	 that	 were	previously	unexplored.	Our	lab	has	shown	that	inhibiting	Spastin	in	the	GBM	cell	 lines	U87	and	T98G	reduces	their	ability	to	form	colonies	in	low	attachment	condition	(soft	
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agar	assay).	In	an	in-vivo	xenograft	mouse	model,	we	have	shown	that	depleting	Spastin	restricts	 the	 tumor	 growth	 significantly	 compared	 to	 the	 control	 mouse.	 With	 this	background,	it	was	critical	to	understand	how	the	cells	behave	differently	under	Spastin	inhibition.	 This	 in-vivo	 experiment	 implied	 that	 Spastin	 was	 required	 by	 the	glioblastoma	cells	to	maintain	tumorigenicity	and	that	led	to	the	next	question	whether	it	 effects	 survival	 of	 the	 cells	 itself.	We	have	 shown	here	 that	 knocking	down	Spastin	using	 two	different	 shRNA	 in	 the	U87	and	T98G,	 cause	apoptosis	 as	 evident	 from	 the	increase	in	the	apoptotic	population	in	the	knockdown	cells.	Furthermore,	we	have	also	shown	that	on	Spastin	depletion	the	cells	show	a	consistent	and	significant	increase	in	the	apoptotic	marker:	Cleaved-PARP	compared	to	the	control.		The	knockdown	cells	also	share	another	phenotype	whereby	they	consistently	lose	cell	attachment	both	 the	U87	and	T98G.	This	 is	not	very	unusual	 considering	 that	Spastin	plays	such	an	essential	role	 in	ensuring	Microtubule	dynamics	and	thereby	effects	cell	adherence	 and	motility.	 Apart	 from	 its	 role	 in	microtubule	 severing,	 Spastin	 also	 has	roles	 in	 membrane	 modeling	 (38)	 and	 maintenance	 of	 the	 ER	 tubular	 network.	 The	localization	of	Spastin	varies	with	the	different	isoforms	as	the	shorter	isoform	lacks	the	hydrophobic	domain.	(39)	Thus	the	isoform	M1	is	found	on	the	ER	and	sometimes	in	an	intermediate	between	the	ER-to-Golgi.	On	the	other	hand	the	M87	isoform	is	often	see	to	 be	 recruited	 on	 the	 endosomes	 and	 has	 co-localization	 with	 microtubules	 hence	primarily	cytosolic	(39)	The	Hydrophobic	domain	in	the	long	isoform	of	Spastin	(M1)	s	predicted	 to	 form	a	hairpin	 loop	 that	 is	 essential	 of	 insertion	 into	 lipid	bilayer	 of	 the	membrane	 and	 helps	 in	maintain	membrane	 curvature	 (38).	 There	 are	 certain	 other	proteins	 in	 the	 cell	 that	 exhibit	 a	 similar	 hairpin	 loop	 domain:	 REEP,	 reticulons	 and	atlastin	(40).	All	 these	proteins	are	 found	on	the	ER	membrane	and	helps	to	maintain	the	integrity.	Surprisingly,	Spastin	is	found	to	interact	with	Atlastin-1	and	REEP1	which	
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again	happen	to	be	HSP	proteins	and	together	they	 	 form	a	complex	referred	to	as	ER	morphogen.	 (38,	41,	42).	Furthermore	 the	ER	 tubular	network	structure	 is	 influenced	by	 the	 microtubule	 dynamics	 and	 hence	 the	 former	 role	 of	 Spastin	 might	 not	 be	mutually	exclusive	from	this	and	they	could	affect	on	another.	Moreover	being	localized	in	endosomes,	 they	have	been	reports	where	abnormal	endosomal	 trafficking	of	Bone	morphogenic	protein	is	observed	in	a	Spastin	HSP	model,	 indicating	its	functional	role	in	endosomal	trafficking	(43).	Thus,	there	is	evidence	of	Spastin	as	machinery	that	links	membrane	modeling	 to	microtubule	 dynamics	 and	 trafficking.	 Thus	 the	 phenotype	 of	cells	losing	attachment	on	Spastin	depletion	is	not	completely	surprising	and	probably	is	 connected	 to	 the	 physiological	 role	 of	 Spastin	 being	 able	 to	 maintain	 membrane	structure	integrity	and	the	trafficking	across	the	compartments.	Eventually	cells	might	compromise	 their	 surface	 integrins	 on	 losing	 Spastin	 which	 thereby	 adversely	 effect	adherence	 and	 holds	 a	 very	 good	 chance	 to	 could	 influence	 large-scale	 signaling	pathways	 downstream	 of	 integrins	 that	 are	 essential	 for	 cell	 survival.	 Two	 such	important	 pathways	 often	 exploited	 by	 cancer	 cells	 is	 the	 ERK	 and	 MAPK	 pathway.	Indeed	 here	we	 see	 that	 on	 Spastin	 depletion	 the	Glioblastoma	 cells	 have	 reduced	 p-ERK	 and	 p-p38	 protein	 levels	 compared	 to	 the	 control.	 	 However	 this	 is	 a	 indirect	correlation	 and	 extensive	 cellular	 experiments	 need	 to	 be	 done	 to	 address	 this	observation.	 For	 future	 experiments,	 it	would	 be	 very	 helpful	 to	 look	 at	 the	 status	 of	Focal	 adhesion	 kinase	 protein	 levels	 that	would	 give	 a	 direct	 idea	 about	 the	 effect	 of	cellular	attachment	and	downstream	signaling.	Most	importantly	in	order	to	prove	that	Spastin	 is	 responsible	 for	 this	 phenotype	 we	 can	 overexpress	 Spastin	 in	 the	glioblastoma	cells	an	look	at	the	levels	of	the	signaling	proteins:	p-ERK,	p-p38	and	FAK	and	we	should	be	able	to	reverse	the	knockdown	phenotype.	Thus,	that	would	primarily	prove	 Spastin’s	 role	 in	 this	 cell	 signaling	 pathways.	 Another	 interesting	 experiment	
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would	be	an	Anoikis	 resistane	experiment.	On	 inhibition	of	 Spastin,	 the	 cells	undergo	Apoptosis	 and	most	 probably	 through	 upregulation	 of	 Bax	 and	Downregulation	Bcl-2	thereby	 turning	 on	 the	 intrinsic	 apoptotic	 cascade.	 Thus	 it	 would	 be	 useful	 to	understand	 whether	 in	 suspension	 these	 Spastin	 depleted	 cells	 can	 survive	 at	 all	compared	to	normal	glioblastoma	cells,	which	is	a	unique	property	of	cancer	cells.	Thus	 overall,	 we	 have	 established	 that	 on	 knocking	 down	 Spastin	with	 two	 different	shRNAs,	the	glioblastoma	cells	are	driven	towards	Apoptosis.	Mechanistically,	this	could	have	happened	by	upregulating	 the	pro-apoptotic	protein	Bax	 and	downregulation	of	the	 anti-apoptotic	 protein	 Bcl-2	 thereby	 moving	 the	 apoptotic	 signal	 forward.	Furthermore,	Spastin	depletion	also	affects	essential	 signaling	pathways	 like	ERK	and	MAPK	as	there	is	a	distinct	decrease	in	p-ERK	and	p-P38	is	observed	when	the	total	ERK	and	p38	remains	almost	constant	between	control	and	knockdown.	In	summary	Spastin	plays	a	key	role	 in	maintaining	the	survival	of	the	glioblastoma	cells	and	its	 inhibition	causes	cell	death.	Thus,	although	extensive	experiments	need	to	be	performed	to	better	understand	 the	 role	 of	 Spastin	 in	 the	 cellular	 signaling	 pathways,	 but	 it	 does	 show	promise	as	a	possible	therapeutic	target	in	Glioblastoma.		 	
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